These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9296240)

  • 1. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
    Scher H; Bishop WP; McCray PB
    Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure.
    De Marco G; Sordino D; Bruzzese E; Di Caro S; Mambretti D; Tramontano A; Colombo C; Simoni P; Guarino A
    Aliment Pharmacol Ther; 2006 Jul; 24(2):387-94. PubMed ID: 16842466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up.
    van de Meeberg PC; Houwen RH; Sinaasappel M; Heijerman HG; Bijleveld CM; Vanberge-Henegouwen GP
    Scand J Gastroenterol; 1997 Apr; 32(4):369-73. PubMed ID: 9140160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
    Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant biliary obstruction.
    Bessone F; Roma MG
    Ann Hepatol; 2016; 15(3):442-7. PubMed ID: 27049500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.
    Kappler M; Espach C; Schweiger-Kabesch A; Lang T; Hartl D; Hector A; Glasmacher C; Griese M
    Aliment Pharmacol Ther; 2012 Aug; 36(3):266-73. PubMed ID: 22670841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants.
    Al-Hathlol K; Al-Madani A; Al-Saif S; Abulaimoun B; Al-Tawil K; El-Demerdash A
    Singapore Med J; 2006 Feb; 47(2):147-51. PubMed ID: 16435058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy with ursodeoxycholic acid in cholestatic liver disease.
    Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP
    Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid therapy in hepatobiliary disease.
    Kowdley KV
    Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.
    Fabris P; Tositti G; Mazzella G; Zanetti AR; Nicolin R; Pellizzer G; Benedetti P; de Lalla F
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1187-93. PubMed ID: 10468700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease.
    Nousia-Arvanitakis S; Fotoulaki M; Economou H; Xefteri M; Galli-Tsinopoulou A
    J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acid abnormalities in cholestatic liver diseases.
    Salen G; Batta AK
    Gastroenterol Clin North Am; 1999 Mar; 28(1):173-93. PubMed ID: 10198784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
    Mazzella G; Rizzo N; Azzaroli F; Simoni P; Bovicelli L; Miracolo A; Simonazzi G; Colecchia A; Nigro G; Mwangemi C; Festi D; Roda E
    Hepatology; 2001 Mar; 33(3):504-8. PubMed ID: 11230728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
    Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
    Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
    Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
    Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement.
    Drzymała-Czyż S; Jończyk-Potoczna K; Lisowska A; Stajgis M; Walkowiak J
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):645-9. PubMed ID: 26882172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cholestasis and cholestatic disorders.
    Sanyal A
    Indian J Gastroenterol; 2001 Mar; 20 Suppl 1():C88-9. PubMed ID: 11293189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.